Full Press Release Details
MedSell commercializes Lumee™ Oxygen tissue monitoring in France, building upon distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now reach approximately 200,000 annual CLI cases in the European Union
Agreement complements KOL collaboration with Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris that accounts for approximately 8% of all CLTI cases in France
BERKELEY, Calif, Dec. 31, 2025 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces a new distributor partnership in France with MedSell. MedSell is a French company that specializes in the commercialization and distribution of innovative medical devices within the French healthcare market by leveraging tailored commercial, marketing, and market-entry support services. As part of its portfolio, Profusa’s new partner will commercialize Lumee Oxygen tissue monitoring in France in both hospital settings and outpatient care, especially in wound care and healing clinics addressing patients with complex and chronic wounds.
Benoit Salaün, Pharm.D., Ph.D., MedSell General Manager, said, “Our collaboration with Profusa stems from our particular interest in Lumee Oxygen tissue monitoring for the large population of patients in France with Critical Limb Threatening Ischemia (CLTI). The device enables the measurement of tissue oxygen perfusion before revascularization, during endovascular or open surgical procedures, and throughout follow-up in hospitals or wound care clinics. We believe Lumee Oxygen tissue monitoring meets a critical unmet clinical need and can bring significant added value to clinicians by supporting decision-making and patient monitoring across the entire treatment pathway.”
With MedSell, Profusa builds upon previously announced distributor partnerships in Spain, Germany, the Benelux countries, Austria, the United Kingdom, and Scandinavia, to now represent more than 200,000 CLI cases annually in the European Union. Further, the distribution partnership with MedSell complements Profusa’s previously announced collaboration with Yann Gouëffic, M.D., Ph.D., professor of vascular surgery in the Vascular Center atGroupe Hospitalier Paris Saint Joseph, Paris, France and a leading surgeon in the field of critical limb threatening ischemia (CLTI). Under the agreement, Pr. Gouëffic adopts Lumee™ oxygen monitoring technology in his practice and in clinical studies that advance application of Lumee for home monitoring. Pr. Gouëffic and his associated practices account for approximately 8% of all CLTI cases in France.
"We are focused on executing on our commercial strategies, including plans to potentially achieve $200 to $250 million in revenue by 2030; capitalize on the near-term as we begin to commercialize inEurope in 2Q 2026with the goal of addressing the US Lumee oxygen opportunity in 2027. We expect todeliver 2026 potential revenue of $0.5 to $2 millionand $9 to $13 million potential revenue in 2027,” said Ben Hwang, Ph.D., Profusa’s Chairman and CEO. “The European clinical community continues to validate our Lumee Oxygen tissue monitoring, including recent presentations of US-based clinical trial data atParis Vascular InsightsandLeipzig Interventional Course. We are committed to making our oxygen tissue monitoring platform easily accessible both at the clinic and at home to improve overall patient outcomes and reduce healthcare costs.”
About Profusa
Based in Berkeley, Calif., Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visithttps://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release (this “Press Release”) may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Such forward-looking statements are subject to risks, uncertainties, and other factors which may be beyond the control of Profusa and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Profusa and its management are inherently uncertain. Profusa cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. There are risks and uncertainties described in the definitive proxy/final prospectus relating to the business combination, which has been filed with the SEC, and in other documents filed by Profusa from time to time with the SEC. These filings may identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Profusa cannot assure you that the forward-looking statements in this communication will prove to be accurate.